Influenza News and Research

Latest Influenza News and Research

Australia's top medical researchers for 2012 announced

Finalists for one of Australia’s longest running and most prestigious awards for medical research were announced today. This year’s winner will join a list of alumni winners that includes many of the country’s most respected scientists.

31 Jul 2012

Progress with GSK in advancing VaxiRNA technology earns Alnylam $3.2M milestone payment

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has earned a development milestone payment from GlaxoSmithKline, totaling $3.2 million. The milestone payment is related to progress in the companies' collaboration on the use of VaxiRNA technology for the production of GSK influenza vaccine.

30 Jul 2012

Promising implications for improving cellular immunotherapy for treatment of cancer

New research from the Trudeau Institute laboratory of Dr. Edward L. Pearce (Washington University) has promising implications for improving a treatment for cancer known as cellular immunotherapy. The findings were just published in the The Journal of Immunology.

30 Jul 2012

UTMB researchers receives NIH grant to develop engineered lung tissue for biomedical studies

University of Texas Medical Branch at Galveston researchers have been awarded a two-year, $1.25 million National Institutes of Health grant to develop a method of custom-growing human lung tissue to make a three-dimensional model for biomedical studies.

30 Jul 2012

Tips to prevent illness in crowds

Massive crowds from around the globe will mingle in London during the Olympics, and that means a world-class array of germs will mix with them. Mayo Clinic infectious diseases expert Gregory Poland, M.D., offers several tips for avoiding illness when you are around lots of people, whether at the Olympics, a professional football game, convention, arena concert or other major event.

26 Jul 2012

Rutgers cell biologist to receive Presidential Early Career Award for Scientists and Engineers

Fewer than 100 researchers nationwide are chosen each year to receive the Presidential Early Career Award for Scientists and Engineers (PECASE), and this year Dr. Nihal Altan-Bonnet is one of the 96 to receive this honor.

25 Jul 2012

Researchers discover bats as reservoir of infections

Measles, mumps, pneumonia, influenza and encephalitis in man, Carré's disease in dogs, Ovine Rinderpest (PPR)… all of these diseases are caused by viruses from the same family: Paramyxoviridae. A vast international study, carried out in collaboration with IRD researchers and published in Nature communications has led to the discovery of more than 60 new species of these dangerous infectious agents, almost double the number previously recorded. This family of highly diverse pathogens affects all animals, from canines to fowl, cattle and humans.

25 Jul 2012

Favorable results from BioCryst’s ulodesine plus allopurinol Phase 2b trial on gout

BioCryst Pharmaceuticals, Inc. announced favorable 52-week safety results and sustained efficacy from the extension phase of its randomized Phase 2b trial of ulodesine (BCX4208) added to allopurinol in patients with gout who had failed to reach the serum uric acid (sUA) therapeutic goal of <6 mg/dL on allopurinol alone, as well as positive Phase 2 safety results in patients with mild to moderate renal impairment.

25 Jul 2012

BioDiem presents positive findings of their eye disease drug at international conference

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced positive results from formal studies of its BDM-E eye disease drug, presented over 21 – 22 July at the International Society for Eye Research (ISER) meeting in Berlin, Germany. The ISER convenes leading researchers and clinicians in the area of eye disease.

22 Jul 2012

Exposure to high-intensity vibrations increases risk of Parkinson's

Severe influenza doubles the odds that a person will develop Parkinson's disease later in life, according to University of British Columbia researchers.

21 Jul 2012

New CHAIT initiative on development of novel immunological therapeutic interventions

The CHAIT initiative is a public-private partnership focusing on the development of novel immunological therapeutic interventions to achieve a 'functional HIV cure' with the ultimate goal of HIV eradication.

21 Jul 2012

BioDiem signs agreement with RMIT to create new non-influenza vaccines

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced that BioDiem has signed an agreement with The Royal Melbourne Institute of Technology (RMIT) regarding a research program that will investigate the use of BioDiem’s live attenuated influenza virus (LAIV) to create new non-influenza vaccines. Developing the potential of the LAIV technology for new indications is an important part of BioDiem’s strategy, and this research is part of the work towards that goal.

19 Jul 2012

Abscisic acid has anti-inflammatory effects in the lungs and gut

Building on previous work with the botanical abscisic acida, researchers in the Nutritional Immunology and Molecular Medicine Laboratory (NIMML) have discovered that abscisic acid has anti-inflammatory effects in the lungs as well as in the gut.

19 Jul 2012

College-age children also need immunizations, says UMDNJ professor

Most parents take their young children regularly for immunization shots that protect against polio, diphtheria, measles, mumps and other diseases. But many do not consider that their college-age children also need immunizations.

14 Jul 2012

Health risks associated with H1N1 vaccine investigated

Results from two studies published in JAMA show that the H1N1 vaccination is associated with a small, but significant, increase in risk for Guillain-Barré syndrome in adults, but does not increase the risk for birth defects or problems when given to pregnant women.

11 Jul 2012

Exposure to H1N1 vaccine in pregnancy does not increase risk of adverse fetal outcomes

In studies examining the risk of adverse outcomes after receipt of the influenza A(H1N1) vaccine, infants exposed to the vaccine in utero did not have a significantly increased risk of major birth defects, preterm birth, or fetal growth restriction; while in another, study researchers found a small increased risk in adults of the nervous system disorder, Guillain-Barre syndrome, during the 4 to 8 weeks after vaccination, according to 2 studies in the July 11 issue of JAMA.

11 Jul 2012

Study assesses risk of GBS following H1N1 vaccine administration

Guillain-Barre syndrome (GBS) is usually characterized by rapidly developing motor weakness and areflexia (the absence of reflexes). "The disease is thought to be autoimmune and triggered by a stimulus of external origin. In 1976-1977, an unusually high rate of GBS was identified in the United States following the administration of inactivated 'swine' influenza A(H1N1) vaccines.

11 Jul 2012

Inovio commences SynCon vaccine phase I study in H1N1 influenza

Inovio Pharmaceuticals, Inc. announced today that the first patients have been treated in a clinical trial evaluating immune responses in elderly adults immunized with Inovio's H1N1 SynCon universal influenza vaccine.

10 Jul 2012

FUJIFILM receives ONC-ATCB certification for Synapse MU 3.0 EHR technology

FUJIFILM Medical Systems U.S.A. announced today that Synapse MU 3.0, is 2011/2012 compliant and was certified as a Complete EHR on June 28, 2012 by the Certification Commission for Health Information Technology, an ONC-ATCB, in accordance with the applicable eligible provider certification criteria adopted by the Secretary of Health and Human Services.

9 Jul 2012

Health officials working to identify respiratory illness responsible for deaths of more than 60 Cambodian children

WHO and Cambodian health officials are investigating "the source of an unidentified illness" -- characterized by high fevers, severe respiratory problems, "and in some cases neurological symptoms" -- that has killed more than 60 children in the country since April, NPR's health blog "Shots" reports (Hensley, 7/5). "

7 Jul 2012

Influenza News and Research

Latest Influenza News and Research

Australia's top medical researchers for 2012 announced

Progress with GSK in advancing VaxiRNA technology earns Alnylam $3.2M milestone payment

Promising implications for improving cellular immunotherapy for treatment of cancer

UTMB researchers receives NIH grant to develop engineered lung tissue for biomedical studies

Tips to prevent illness in crowds

Rutgers cell biologist to receive Presidential Early Career Award for Scientists and Engineers

Researchers discover bats as reservoir of infections

Favorable results from BioCryst’s ulodesine plus allopurinol Phase 2b trial on gout

BioDiem presents positive findings of their eye disease drug at international conference

Exposure to high-intensity vibrations increases risk of Parkinson's

New CHAIT initiative on development of novel immunological therapeutic interventions

BioDiem signs agreement with RMIT to create new non-influenza vaccines

Abscisic acid has anti-inflammatory effects in the lungs and gut

College-age children also need immunizations, says UMDNJ professor

Health risks associated with H1N1 vaccine investigated

Exposure to H1N1 vaccine in pregnancy does not increase risk of adverse fetal outcomes

Study assesses risk of GBS following H1N1 vaccine administration

Inovio commences SynCon vaccine phase I study in H1N1 influenza

FUJIFILM receives ONC-ATCB certification for Synapse MU 3.0 EHR technology

Health officials working to identify respiratory illness responsible for deaths of more than 60 Cambodian children

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Influenza News and Research

Latest Influenza News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in